US precision oncology company Enliven Therapeutics (Nasdaq: ELVN) today announced that, concurrent with the completion of its previously announced merger with Imara, it has completed a $165 million private placement.
The placement was co-led by new investors Fairmount and Venrock Healthcare Capital Partners, with participation from additional new investors, including Fidelity Management & Research Company, RA Capital Management, Frazier Life Sciences and Commodore Capital, and support from Enliven’s existing institutional investors.
The company, whose newly-listed shares began trading today, is expected to have a cash runway through multiple clinical milestones and into early 2026. Its share gained 2.6% to $4.00 in pre-market activity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze